Cargando…

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia

Great effort is spent on developing therapies to improve the dire outcomes of those diagnosed with acute myeloid leukemia. The methods for quantifying response to therapeutic intervention have however lacked sensitivity. Patients achieving a complete remission as defined by conventional cytomorpholo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dillon, Laura W., Hayati, Sheida, Roloff, Gregory W., Tunc, Ilker, Pirooznia, Mehdi, Mitrofanova, Antonina, Hourigan, Christopher S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355494/ https://www.ncbi.nlm.nih.gov/pubmed/30171026 http://dx.doi.org/10.3324/haematol.2018.203133

Ejemplares similares

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
por: Roloff, Gregory W., et al.
Publicado: (2017)

The present and future of measurable residual disease testing in acute myeloid leukemia
por: Blachly, James S., et al.
Publicado: (2022)

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia
por: Gui, Gege, et al.
Publicado: (2023)

Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer
por: Panja, Sukanya, et al.
Publicado: (2018)

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
por: Yoest, Jennifer M., et al.
Publicado: (2020)

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
por: Buccisano, Francesco, et al.
Publicado: (2018)

Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study
por: Scott, Stuart, et al.
Publicado: (2023)

Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia
por: Kim, Seon Young, et al.
Publicado: (2023)

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2022)

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
por: Azenkot, Tali, et al.
Publicado: (2022)

Improved detection of measurable residual disease in acute myeloid leukemia
por: Zhang, Xuan, et al.
Publicado: (2023)

UMAP Based Anomaly Detection for Minimal Residual Disease Quantification within Acute Myeloid Leukemia
por: Weijler, Lisa, et al.
Publicado: (2022)

Network Analysis and Transcriptome Profiling Identify Autophagic and Mitochondrial Dysfunctions in SARS-CoV-2 Infection
por: Singh, Komudi, et al.
Publicado: (2020)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
por: Ramakrishnan, Anitha, et al.
Publicado: (2023)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
por: Tettero, Jesse M., et al.
Publicado: (2021)

The transcription factors TFE3 and TFEB amplify p53 dependent transcriptional programs in response to DNA damage
por: Brady, Owen A, et al.
Publicado: (2018)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
por: Aitken, Marisa J. L., et al.
Publicado: (2021)

Delving the depths of measurable residual disease negativity in acute myeloid leukemia
por: Freeman, Sylvie D.
Publicado: (2022)

Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia
por: Li, Xueyao, et al.
Publicado: (2023)

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia
por: Kim, TaeHyung, et al.
Publicado: (2020)

FLT3-ITD Measurable Residual Disease Monitoring in Acute Myeloid Leukemia Using Next-Generation Sequencing
por: Lee, Jong-Mi, et al.
Publicado: (2022)

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
por: Röhnert, Maximilian A., et al.
Publicado: (2022)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Correction Notice: Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Publicado: (2022)

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia
por: Ahmadmehrabi, Khashayar, et al.
Publicado: (2021)

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response
por: Wong, Hong Yuen, et al.
Publicado: (2019)

Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
por: Božić, Tanja, et al.
Publicado: (2021)

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection
por: Srinivasan Rajsri, Kritika, et al.
Publicado: (2023)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
por: Buckley, Sarah A., et al.
Publicado: (2017)

Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia
por: Liu, Fu-Jia, et al.
Publicado: (2021)

Random survival forest model identifies novel biomarkers of event-free survival in high-risk pediatric acute lymphoblastic leukemia
por: Bohannan, Zachary S., et al.
Publicado: (2022)

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
por: Levine, Ross L., et al.
Publicado: (2019)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
por: Pratz, Keith W., et al.
Publicado: (2022)

Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia
por: Purev, Enkhtsetseg, et al.
Publicado: (2014)

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia
por: Jentzsch, Madlen, et al.
Publicado: (2019)

The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia
por: Fang, Qiuyun, et al.
Publicado: (2022)

P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
por: Tettero, Jesse, et al.
Publicado: (2023)

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
por: Patkar, Nikhil, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oqerle6j7tooebdmb7gin9o9u7